Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.

@article{LerouxRoels2014ImmunogenicityAS,
  title={Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.},
  author={Geert G. Leroux-Roels and Patricia Bourguignon and Julie Willekens and Michel Janssens and Fr{\'e}d{\'e}ric Cl{\'e}ment and Arnaud M Didierlaurent and Laurence A Fissette and François Roman and Dominique Boutriau},
  journal={Clinical and vaccine immunology : CVI},
  year={2014},
  volume={21 3},
  pages={
          302-11
        }
}
This phase II study evaluated the effect of chloroquine on the specific CD8(+) T-cell responses to and the safety of a booster dose of investigational human immunodeficiency virus type 1 (HIV-1) F4/AS01(B) vaccine containing 10 μg of recombinant fusion protein (F4) adjuvanted with the AS01(B) adjuvant system. Healthy adults aged 21 to 41 years, primed 3 years before with two F4/AS01(B) doses containing 10 or 30 μg of F4 (ClinicalTrials.gov registration number NCT00434512), were randomized (1:1… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-6 OF 6 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

An Adjuvanted Polyprotein HIV-1 Vaccine Induces Polyfunctional Cross-Reactive CD4+ T Cell Responses in Seronegative Volunteers

VIEW 10 EXCERPTS

Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo

VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL